Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Current Diagnostics for Prostate Cancer

Danielle Whiting  1 , Simon RJ Bott  1
Simon RJ Bott  1 , Keng Lim Ng  1
, editors.
In: Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 4.
Affiliations
Free Books & Documents
Review

Current Diagnostics for Prostate Cancer

Danielle Whiting et al.
Free Books & Documents

Excerpt

How prostate cancer is diagnosed and staged is an ever-evolving field. It plays a fundamental role in ensuring the appropriate therapeutic options are offered to the patient whilst preventing overdiagnosis and overtreatment. Despite the numerous advances in the field, a suspicion of prostate cancer continues to arise from digital rectal examination and measurement of serum prostate specific antigen (PSA). Additional derivatives of serum PSA along with urinary biomarkers and multiparametric magnetic resonance imaging can then help to risk stratify patients in order to appropriately counsel them on the risks and benefits of a prostate biopsy. After a diagnosis of prostate cancer is reached, further staging may be required and can be achieved by a variety of imaging techniques such as computed tomography (CT), bone scintigraphy, and prostate specific membrane antigen-based positron-emission tomography/CT. In this chapter, we review the current role of these and other diagnostic tools in prostate cancer.

PubMed Disclaimer

References

    1. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate. 2008;68(9):985–93. https://doi.org/10.1002/pros.20759. - DOI - PubMed
    1. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42(4):365–74. https://doi.org/10.1016/0090-4295(93)90359-I. - DOI - PubMed
    1. Thompson IM, Pauller DK, Goodman PJ, Tangen CM, Scott Lucia M, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0ng per millilitre. N Engl J Med. 2004;350(22):2239–46. https://doi.org/10.1056/NEJMoa031918. - DOI - PubMed
    1. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, et al. Variation of serum prostate specific antigen levels. JAMA;2003;289(20):2695–700. https://doi.org/10.1001/jama.289.20.2695. - DOI - PubMed
    1. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860–4. https://doi.org/10.1001/jama.1993.03510070082041. - DOI - PubMed

LinkOut - more resources